In comedy, the more you can surprise the audience by subverting their expectations, the better. There is nothing better than coming up with a brilliant set piece, something that writers and actors can ...

In medieval Denmark, people could pay for more prestigious graves closer to the church — a sign of wealth and status. But when researchers examined hundreds of skeletons, they discovered something ...

There are two kinds of Monty Python fans: casual rewatchers and the devotees who can quote every sketch from memory. If ...

Beckoning audiences on a whimsical jaunt to always look on the bright side of life, the touring revival of “Spamalot” is especially winning for its unabashed determination to deliver on all manners of ...

Scientists may have spotted a long-sought triplet superconductor — a material that can transmit both electricity and electron spin with zero resistance. That ability could dramatically stabilize ...

The biotech is developing a test to detect multiple cancers. However, a recent clinical trial did not produce the hoped-for results. The share price will likely remain low unless Grail has more ...

Hello and welcome to Energy Source, coming to you from New York, where oil prices have surged above $70 following a report that Washington could take military action against Iran sooner than ...

GRAIL Inc. (NASDAQ: GRAL) stock plunged during Friday’s premarket session following the announcement of results from the NHS-Galleri trial, which evaluated the effectiveness of the Galleri test in ...

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...

Grail (GRAL) on Friday announced topline results from the landmark, randomized, controlled NHS-Galleri trial, which evaluated annual multi-cancer screening with the Galleri test in England's National ...

Just weeks after filing for FDA approval of its Galleri blood test for cancer screening, Grail has reported that a flagship trial of the technology in the UK failed to achieve its primary objective.

This article first appeared on GuruFocus. Grail (NASDAQ:GRAL) shares tumbled almost 50% on Friday after its three-year cancer screening trial missed its main goal, a setback for the blood test maker.